Review of panitumumab: a targeted therapy.
Winkeljohn
Debra L
DL
Clinical Director, Hematology Oncology Associates, Albuquerque, NM, USA. dwinkelijohn@comcast.net
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000451:nursing*; D003967:Diarrhea / Q000139:chemically induced; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D016503:Drug Delivery Systems; D003875:Drug Eruptions / Q000209:etiology; D016903:Drug Monitoring; D006801:Humans; D024802:Nurse's Role; D009859:Oncology Nursing / Q000379:methods*; D000077544:Panitumumab; D018579:Patient Selection; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077544:Panitumumab; D000068818:Cetuximab